Hormone pill before PSMA scan for high-risk prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests if giving a short-term hormone pill (relugolix) before a special PSMA PET/CT scan makes the scan clearer for men with high-risk prostate cancer. It may help doctors better see where the cancer is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with high-risk or very high-risk prostate cancer (such as a Gleason score of 4 or 5, PSA over 20, or tumor on MRI).
- Your testosterone level must be at least 300 (a normal level).
- You cannot have had prior hormone therapy, chemotherapy in the last 2 weeks, or pelvic radiation.
- You must be able to use condoms or abstinence during sex (to protect partners) while on the study drug.
- You need to have normal blood counts and be well enough for daily activities (ECOG score 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new hormone pill called relugolix combined with radiation therapy for men with high-risk prostate cancer. The goal is to see if this combination improves treatment outcomes.
This trial tests a treatment called Lu-177-PSMA-617 given before surgery for high-risk prostate cancer that has spread only to nearby lymph nodes. It aims to see if this approach helps control the cancer before the prostate is removed.
This trial tests whether combining two hormone therapy drugs, relugolix and enzalutamide, with radiation therapy can help treat very high-risk prostate cancer. The goal is to see if this combination is safe and effective for men whose cancer has a high chance of coming back.
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
This study looks at how a prostate-specific scan marker (PSMA) changes after you start or continue hormone therapy. It may help doctors better understand who responds and how quickly prostate cancer biology shifts during treatment.
This trial tests a new way to plan radiation for high-risk prostate cancer. Doctors will use a special PET scan (PSMA PET) to find the main tumor inside the prostate and give it a stronger dose of radiation, along with standard hormone therapy. This approach might improve outcomes for patients with aggressive disease.
Hear when a new Prostate Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.